Elevated glutathione levels protected HepG2 cells not only from oxidative stress (generated by the redox cycler, paraquat) but also from mechanistically diverse stressors such as the inhibition of mitochondrial complex I by rotenone or the inhibition of the proteasomal system by MG-132 and bortezomib (Suppl
Limited clinical validation: Despite decades of research interest, DSIP has not progressed into wide-scale clinical adoption, which raises questions about consistency and reproducibility of effects

However, some secondary measures of nerve impairment did improve, especially in participants with higher cardiovascular risk and moderate BMI.7 Shorter-term trials have shown that 600mg/day of oral racemic ALA reduced neuropathy symptoms like burning, tingling, and numbness in as little as 35 weeks.4 20 A 2010 meta-analysis concluded that oral ALA can improve symptoms of diabetic neuropathy, but noted variability in effect sizes across trials and better results with intravenous administration.1 Despite promising results from some trials, a recent systematic review evaluating eight randomized controlled trials indicates that findings on ALA's effectiveness in treating diabetic neuropathy symptoms are inconsistent.23 While ALA proved safe and tolerable across these studies, the review concluded that definitive evidence supporting significant benefits is limited
Dehydrated skin is more prone to scarring, so hyaluronic acid provides a vital boost
DSIPs side effect profile appears mild compared to pharmaceutical sleep aids, with most reported effects relating to dose or timing issues rather than inherent toxicity